191 related articles for article (PubMed ID: 19092780)
21. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy.
Yin Y; Yuan X; Gao H; Yang Q
Int J Pharm; 2020 Jan; 573():118785. PubMed ID: 31678384
[TBL] [Abstract][Full Text] [Related]
22. Molecularly targeted therapy: when to stop and when to continue?
Hirsch FR; Mok TS; Borges V; Bunn PA
Lancet Oncol; 2010 Aug; 11(8):709-11. PubMed ID: 20570560
[No Abstract] [Full Text] [Related]
23. A dose of reality for rational therapies.
Nat Biotechnol; 2005 Mar; 23(3):267. PubMed ID: 15765066
[No Abstract] [Full Text] [Related]
24. Targeting RAS-ERK signalling in cancer: promises and challenges.
Samatar AA; Poulikakos PI
Nat Rev Drug Discov; 2014 Dec; 13(12):928-42. PubMed ID: 25435214
[TBL] [Abstract][Full Text] [Related]
25. Bundling next-generation cancer therapies for synergy.
Kling J
Nat Biotechnol; 2006 Aug; 24(8):871-2. PubMed ID: 16900109
[No Abstract] [Full Text] [Related]
26. Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo.
Wang M; Du Q; Zuo L; Xue P; Lan C; Sun Z
Curr Drug Metab; 2020; 21(13):996-1008. PubMed ID: 33183197
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.
Janssen JM; Dorlo TPC; Steeghs N; Beijnen JH; Hanff LM; van Eijkelenburg NKA; van der Lugt J; Zwaan CM; Huitema ADR
Clin Pharmacol Ther; 2020 Sep; 108(3):494-505. PubMed ID: 32022898
[TBL] [Abstract][Full Text] [Related]
28. Take-home message: are we "off target"?
Khurdayan VK
Drug News Perspect; 2007 Jun; 20(5):345-51. PubMed ID: 17878963
[TBL] [Abstract][Full Text] [Related]
29. Moving towards dose individualization of tyrosine kinase inhibitors.
Klümpen HJ; Samer CF; Mathijssen RH; Schellens JH; Gurney H
Cancer Treat Rev; 2011 Jun; 37(4):251-60. PubMed ID: 20833478
[TBL] [Abstract][Full Text] [Related]
30. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
[TBL] [Abstract][Full Text] [Related]
31. Calmodulin kinase II as a target for inhibition in cardiac disease.
Doggrell SA
Expert Opin Ther Targets; 2005 Dec; 9(6):1319-21. PubMed ID: 16300478
[No Abstract] [Full Text] [Related]
32. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
[TBL] [Abstract][Full Text] [Related]
33. Kinase inhibitors in prostate cancer.
Limvorasak S; Posadas EM
Anticancer Agents Med Chem; 2009 Dec; 9(10):1089-104. PubMed ID: 19925393
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of food-drug interactions with small-molecule kinase inhibitors.
Veerman GDM; Hussaarts KGAM; Jansman FGA; Koolen SWL; van Leeuwen RWF; Mathijssen RHJ
Lancet Oncol; 2020 May; 21(5):e265-e279. PubMed ID: 32359502
[TBL] [Abstract][Full Text] [Related]
35. Targeting protein kinases.
Melnikova I; Golden J
Nat Rev Drug Discov; 2004 Dec; 3(12):993-4. PubMed ID: 15645605
[No Abstract] [Full Text] [Related]
36. Are targeted therapies really targeted?
Schilsky RL
Clin Adv Hematol Oncol; 2003 Dec; 1(12):722-3. PubMed ID: 16258475
[No Abstract] [Full Text] [Related]
37. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
Terada T; Noda S; Inui K
Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
[TBL] [Abstract][Full Text] [Related]
38. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
Solomon B; Wilner KD; Shaw AT
Clin Pharmacol Ther; 2014 Jan; 95(1):15-23. PubMed ID: 24091716
[TBL] [Abstract][Full Text] [Related]
39. Proposome for transdermal delivery of tofacitinib.
Kathuria H; Nguyen DTP; Handral HK; Cai J; Cao T; Kang L
Int J Pharm; 2020 Jul; 585():119558. PubMed ID: 32565283
[TBL] [Abstract][Full Text] [Related]
40. Strategies to overcome resistance to targeted protein kinase inhibitors.
Daub H; Specht K; Ullrich A
Nat Rev Drug Discov; 2004 Dec; 3(12):1001-10. PubMed ID: 15573099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
